Mucin Glycosylating Enzymes in Head and Neck Cancers
- Conditions
- Glycosyltion Enzymes and Function Abnormalities
- Registration Number
- NCT01976377
- Lead Sponsor
- National Taiwan University Hospital
- Brief Summary
Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.
- Detailed Description
Glycosylation is the most common post-translational modification of proteins. Aberrant glycosylation is the hallmark of most human cancers and affect many cellular properties, including cell proliferation, apoptosis, differentiation, transformation, migration and immune response.
Though widely explored in various human cancers, the role of mucin glycosylating enzymes in HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- Head and neck cancer patients receiving operation in National Taiwan University Hospital
- Recurrence or non-operable patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measure the expression of mucin glycosylating in head and neck cancer 1~5 years after patient received surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Taiwan University
🇨🇳Taipei, Taiwan